Top Story Today
A Cancer Drug That Picks the Lock on Cells That Refuse to Die
The FDA granted accelerated approval to Beqalzi (sonrotoclax), the first BCL-2 inhibitor ever greenlit specifically for mantle cell lymphoma. It's a daily pill for patients who've already failed at least two prior treatments, including a BTK inhibitor. In a trial of 103 heavily pretreated patients, 52% responded, and responses lasted a median of 15.8 months. That's significant for a population where survival without further treatment averages just 5.5 months. The catch: it's a conditional approval, and a confirmatory trial still needs to prove the drug truly extends lives.
Why it matters: As the 14th novel drug approval of 2026, Beqalzi fills a critical gap between failed BTK therapy and the $600,000+ logistical nightmare of CAR-T, giving a vulnerable patient population an outpatient-friendly option that could reshape the MCL treatment sequence.
Read more →Clinical and Regulatory
U.S. Biotechs Are Quietly Moving Their Earliest Trials Overseas
Multiple U.S. biotech companies are shifting first-in-human trials to Europe and Australia as FDA staffing cuts (roughly 3,859 employees lost) shake confidence in American regulatory timelines. Australia offers trials 30-40% cheaper with six-to-eight-week startup times. One CEO called the irony of offshoring drug development during an "America First" administration impossible to ignore.
Read more →Biogen's Alzheimer's Drug Missed Its Endpoint. Phase 3 Is Happening Anyway.
Biogen's tau-targeting drug diranersen failed to hit its primary endpoint in the Phase 2 CELIA trial, yet the company is advancing to Phase 3. The reason: every dose slowed cognitive decline versus placebo in pre-specified analyses, and the drug produced sustained reductions in both soluble tau and tau tangles on brain scans, a combination no previous tau therapy has ever achieved.
Read more →Takeda Goes 0-for-4 in Nausea and Vomiting After Axing Another Program
Takeda killed its fourth consecutive nausea and vomiting candidate, TAK-004, leaving the GI-focused pharma giant with zero active programs in the space. All four failures targeted similar peptide biology, raising questions about whether the underlying scientific thesis was flawed from the start.
Read more →Deals and M&A
Two Suitors Fought Over a Shrinking Pharma Company. The Winner Paid 76% Extra.
Zydus Lifesciences won a bidding war for Assertio Holdings at $23.50 per share, a 75.8% premium over the pre-deal stock price. The twist: Assertio is essentially a single-product company with declining revenue and no pipeline. The real prize was its $95 million cash pile and a commercial oncology drug called Rolvedon.
Read more →Fosun Drops $60M on an Alzheimer's Pill Before Seeing Phase 3 Data
Fosun Pharma paid $60 million for an option to license AriBio's oral Alzheimer's drug AR1001, a daily PDE5 inhibitor that attacks the disease through multiple mechanisms at once. The deal could reach $4.7 billion if Phase 3 results (expected this year) deliver, making it the largest Alzheimer's licensing deal by a Korean company.
Read more →Company Moves
Lexicon's CEO Has $200M and Plans to 'Go Crazy'
Lexicon Pharmaceuticals nearly doubled its cash to $200 million, shrank its quarterly loss by 96%, and now its CEO is signaling aggressive expansion. The company has four pipeline catalysts due within 12 months, including a Phase 3 hypertrophic cardiomyopathy readout and a potential FDA resubmission for Type 1 diabetes.
Read more →ICON Bets Big on San Antonio With a 120-Bed Clinical Research Campus
One of the world's largest CROs opened a 69,500-square-foot research facility in San Antonio with satellite clinics in Houston and Kansas, betting that early-phase drug testing needs to move beyond coastal hubs. With 80% of trials delayed by recruitment shortfalls, the play is simple: put the clinic where the patients actually live.
Read more →